Source-grounded facts extracted from Crinetics Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2026 results: revenue $10.7 million. Guidance reaffirmed.
“ACTH antagonist, atumelnant, in a broad population including patients with both Cushing’s disease and ectopic ACTH syndrome. First Quarter 2026 Financial Results: • Revenue was $10.7 million for the quarter ended March 31, 2026, compared to $0.4 million for the same period in 2025. Revenue for the quarter ended March 31, 2026 includes $10.3 million in net product”
Auditor Changes
Crinetics Pharmaceuticals, Inc. engaged PricewaterhouseCoopers LLP as its auditor.
“(b) Appointment of New Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee approved the appointment of PricewaterhouseCoopers LLP (“PwC”) as the Company’s new independent registered public accounting firm for the fiscal year ended December 31, 2026.”
Auditor Changes
Crinetics Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its auditor.
“(a) Dismissal of Independent Registered Public Accounting Firm On February 27, 2026, the Audit Committee (the "Audit Committee") of the Board of Directors of Crinetics Pharmaceuticals, Inc. (the "Company") approved the dismissal of BDO USA, P.C. ("BDO") as the Company’s independent registered public accounting firm.”
Marc Wilson resigned as other at Crinetics Pharmaceuticals, Inc..
“pursuant to which Mr. Wilson resigned as an employee of the Company, effective April 1, 2025”
Tobin "Toby" Schilke was appointed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
“On February 24, 2025, Crinetics Pharmaceuticals, Inc. (the “Company” or “Crinetics”) announced the appointment of Tobin “Toby” Schilke as Chief Financial Officer, which will be effective as of February 28, 2025.”
James Hassard departed as Chief Operating Officer at Crinetics Pharmaceuticals, Inc..
“James Hassard ceased serving as the Chief Operating Officer of the Company, effective October 14, 2024.”
James Hassard departed as Chief Commercial Officer at Crinetics Pharmaceuticals, Inc..
“On September 13, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) determined that James Hassard will separate from the Company and will cease serving as the Chief Commercial Officer, effective October 14, 2024.”
Marc Wilson departed as Chief Financial Officer at Crinetics Pharmaceuticals, Inc..
“On August 5, 2024, Marc Wilson notified the Company of his decision to step down from his position as Chief Financial Officer of the Company.”
Earnings Releases
Crinetics Pharmaceuticals, Inc. reported the first quarter ended March 31, 2024 results: revenue $0.6 million, net income $66.9 million.
“of $5.6 million. • Net loss for the three months ended March 31, 2024, was $66.9 million, compared to a net loss of $46.0 million for the same period in 2023. • Revenues were$0.6 million for the three months ended March 31, 2024, compared to $2.7 million for the same period in 2023. Revenues were derived from licensing arrangements for our paltusotine product”
Material Agreements
Crinetics Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional accredited investors named therein valued at aggregate gross proceeds from the Private Placement of approximately $350 million (effective 2024-02-27).
“On February 27, 2024, Crinetics Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors named therein (the “Purchasers”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “Private Placement”) an aggregate of 8,333,334 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”), at a purchase price of $ 42.00 per share.”
Earnings Releases
Crinetics Pharmaceuticals, Inc. reported the fourth quarter and full year ended December 31, 2023 results: revenue $4.0 million, net income net loss of $214.5 million.
“ended December 31, 2022 and $1.0 million for the year ended December 31, 2022. This loss was derived from the company’s investment in Radionetics Oncology, Inc. • Revenues were $4.0 million for the full year ended December 31, 2023, compared to $4.7 million for the same period in 2022. There were no revenues for the three months ended December 31, 2023, compared to”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.